Elicio Therapeutics, Inc. (ELTX) Discusses Camupepimut Development in Neoadjuvant and Metastatic Pancreatic Cancer Transcript
Elicio Therapeutics, Inc. ( ELTX ) Discusses Camupepimut Development in Neoadjuvant and Metastatic Pancreatic Cancer November 11, 2026 2:30 PM EST Company Participants Christopher Haqq - Executive VP, Head of Research & …
● GlobeNewsWireNov 5, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, to…
● GlobeNewsWireNov 4, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, t…
● GlobeNewsWireOct 29, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting
Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer Additional preclinical poster presentati…
● GlobeNewsWireOct 23, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine
BOSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, t…
● GlobeNewsWireSep 24, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancer Findings are expected to inform a refined Phase 3 de…
● GlobeNewsWireAug 31, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, to…
● GlobeNewsWireAug 24, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, to…
Article counts from the last market-wide feed page, across every symbol we track and not just ELTX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.